Follicular Lymphoma Pipeline 2025: Advancing Hematological Cancer Therapies

DelveInsight's "Follicular Lymphoma Pipeline Insight, 2025" report offers in-depth analysis of over 45 companies and more than 50 pipeline drugs in the Follicular Lymphoma treatment arena. It includes detailed profiles of Follicular Lymphoma pipeline drugs, spanning clinical and nonclinical development phases. Furthermore, it evaluates Follicular Lymphoma pipeline therapeutics by product category, development stage, administration route, and molecular type. It also highlights discontinued pipeline products in this domain.

Request a sample and discover the recent advances in Follicular Lymphoma Treatment Drugs @ Follicular Lymphoma Pipeline Outlook Report

Key Takeaways from the Follicular Lymphoma Pipeline Report

• In August 2025, Celgene disclosed a trial structured as a multicenter, randomized, open-label Phase 3 study to assess the effectiveness and safety of golcadomide combined with rituximab versus investigator's choice in participants with relapsed/refractory follicular lymphoma who have undergone at least one prior systemic therapy.

• In August 2025, Epizyme, Inc. conducted a trial to evaluate the safety and the extent to which adverse effects of each study drug combination can be tolerated (known as tolerability). It is also intended to establish a recommended study drug dosage for stages 2 and 3. Stage 1 of the study is completed.

• In August 2025, Hoffmann-La Roche disclosed a trial to assess the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len versus subcutaneous (SC) mosunetuzumab + len.

• DelveInsight's Follicular Lymphoma Pipeline analysis illustrates a vibrant field with over 45 Follicular Lymphoma companies developing more than 50 pipeline treatment therapies.

• The prominent Follicular Lymphoma Companies include Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others.

• Promising Follicular Lymphoma Pipeline Therapies include DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.

Find out more about Follicular Lymphoma Therapeutics Assessment @ Follicular Lymphoma Preclinical and Discovery Stage Products

Follicular Lymphoma Emerging Drugs

• MIL62: MAB WORKS MIL62 is a third-generation anti-CD20 antibody with a distinctive competitive edge. MIL62 is the first domestically developed third-generation anti-CD20 antibody entering Phase III registration trial in China. MIL62 is self-developed using our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 shows stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (another third-generation anti-CD20 antibody). The company is pursuing critical clinical development strategies to first obtain marketing approval from the NMPA for relapsed and/or refractory FL patients and DLBCL patients. Simultaneously, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab. The drug is currently in Phase III trials for follicular lymphoma.

• AZD0486: AstraZeneca AZD0486, also known as TNB-486, is an innovative bispecific antibody targeting CD19 and CD3, designed to boost T-cell-mediated destruction of malignant B cells, especially in patients with relapsed or refractory follicular lymphoma (FL). AZD0486 works by recruiting T-cells to attack B-cell malignancies, thereby overcoming some limitations of traditional therapies. Its design includes a low-affinity anti-CD3 moiety, which helps reduce severe cytokine release syndrome (CRS), a common side effect of T-cell engagers. This unique feature enables a more controlled immune response, potentially leading to improved safety profiles. The drug is currently in Phase III clinical trials for Follicular Lymphoma.

• Abexinostat: Xynomic Pharmaceuticals Abexinostat (Abx) is a novel, potent, orally administered pan-histone deacetylase inhibitor (HDACi) developed by Xynomic Pharmaceuticals. It is engineered to maintain effective anti-tumor concentrations through twice-daily (BID) dosing. Abexinostat targets multiple HDAC enzymes, which are involved in the deacetylation of histones, leading to chromatin remodeling and regulation of gene expression. By inhibiting HDACs, Abexinostat causes the accumulation of acetylated histones, promoting apoptosis, cell cycle arrest, and inhibition of angiogenesis in cancer cells. Additionally, Abexinostat acts as a Rad51 recombinase inhibitor, interfering with DNA repair mechanisms, which enhances its anti-cancer activity. The drug is in Phase II clinical trials for Follicular Lymphoma.

• ABBV-319: AbbVie ABBV-319 is a CD19-targeting antibody-drug conjugate designed to minimize glucocorticoid-associated toxicities while possessing 3 distinct mechanisms of action (MOA) to boost therapeutic efficacy: (1) antibody-mediated delivery of a glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced fragment crystallizable (Fc)-mediated effector function via afucosylation of the antibody backbone. The drug is in Phase I development for Follicular Lymphoma.

• NX-2127: Nurix Therapeutics, Inc. NX-2127 is an oral small molecule degrader of BTK and cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos). Cereblon immunomodulatory drugs that induce degradation IKZF1 and IKZF3 such as lenalidomide and pomalidomide are FDA approved for various hematologic malignancies including multiple myeloma, follicular lymphoma, and mantle cell lymphoma. We hypothesize that the combination of BTK degradation and cereblon immunomodulatory activity will have enhanced therapeutic benefit in patients suffering from a variety of B-cell malignancies. Initial clinical data support the activity of NX-2127 in patients whose tumors harbor either wild-type BTK or BTK with mutations conferring clinical resistance to FDA approved agents. Initial clinical data also confirm potent BTK degradation with once daily oral dosing. The drug is in Phase I trials for Follicular Lymphoma.

The Follicular Lymphoma pipeline report provides insights into

• The report offers detailed information on companies developing therapies for Follicular Lymphoma, including the total therapies each company is advancing.

• It reviews various therapeutic candidates divided into early-stage, mid-stage, and late-stage development for Follicular Lymphoma treatment.

• Follicular Lymphoma Companies are focused on targeted therapeutics with active and inactive (dormant or discontinued) projects.

• Follicular Lymphoma Drugs in development, categorized by development stage, administration route, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular type.

• In-depth analysis of collaborations (company-to-company and company-academia partnerships), licensing agreements, and financing details to support future progress in the Follicular Lymphoma market.

Explore the dynamic world of drug development with our latest Follicular Lymphoma Pipeline Insights report! Don't miss this opportunity to stay informed-download now! @ Follicular Lymphoma Treatment Drugs

Follicular Lymphoma Companies Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others.

Follicular Lymphoma pipeline report evaluates the therapeutic potential of pipeline drugs by Route of Administration. Products are classified under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Follicular Lymphoma Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Learn more about the emerging Follicular Lymphoma Pipeline Therapies @ Follicular Lymphoma Clinical Trials Assessment

Scope of the Follicular Lymphoma Pipeline Report

• Coverage- Global

• Follicular Lymphoma Companies- Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others.

• Follicular Lymphoma Pipeline Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.

• Follicular Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Follicular Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Follicular Lymphoma Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!" @ Follicular Lymphoma Emerging Drugs and Companies

Table of Contents

1. Introduction

2. Executive Summary

3. Follicular Lymphoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Follicular Lymphoma- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. MIL62: MAB WORKS

9. Mid Stage Products (Phase II)

10. Abexinostat: Xynomic Pharmaceuticals

11. Early Stage Products (Phase I)

12. ABBV-319: AbbVie

13. Preclinical and Discovery Stage Products

14. Drug name: Company name

15. Inactive Products

16. Follicular Lymphoma Key Companies

17. Follicular Lymphoma Key Products

18. Follicular Lymphoma- Unmet Needs

19. Follicular Lymphoma- Market Drivers and Barriers

20. Follicular Lymphoma- Future Perspectives and Conclusion

21. Follicular Lymphoma Analyst Views

22. Follicular Lymphoma Key Companies

23. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us 

Kanishk

kkumar@delveinsight.com